These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 19064772)
1. Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Feuerstein GZ; Chavez J Stroke; 2009 Mar; 40(3 Suppl):S121-5. PubMed ID: 19064772 [TBL] [Abstract][Full Text] [Related]
2. Improving the efficiency of the development of drugs for stroke. Howells DW; Sena ES; O'Collins V; Macleod MR Int J Stroke; 2012 Jul; 7(5):371-7. PubMed ID: 22712738 [TBL] [Abstract][Full Text] [Related]
3. Time for a neurorestorative therapy in stroke. Jäkälä P; Jolkkonen J Expert Opin Biol Ther; 2012 Mar; 12(3):267-70. PubMed ID: 22251201 [TBL] [Abstract][Full Text] [Related]
4. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Savitz SI; Fisher M Ann Neurol; 2007 May; 61(5):396-402. PubMed ID: 17420989 [TBL] [Abstract][Full Text] [Related]
7. From biomarker strategies to biomarker activities and back. van Gool AJ; Henry B; Sprengers ED Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413 [TBL] [Abstract][Full Text] [Related]
8. Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke. Greenhalgh AD; Ogungbenro K; Rothwell NJ; Galea JP Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):681-95. PubMed ID: 21521135 [TBL] [Abstract][Full Text] [Related]
9. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. Calabrese EJ Crit Rev Toxicol; 2008; 38(6):557-77. PubMed ID: 18615310 [TBL] [Abstract][Full Text] [Related]
10. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Philip M; Benatar M; Fisher M; Savitz SI Stroke; 2009 Feb; 40(2):577-81. PubMed ID: 19074479 [TBL] [Abstract][Full Text] [Related]
11. Importance of preclinical research in the development of neuroprotective strategies for ischemic stroke. Neuhaus AA; Rabie T; Sutherland BA; Papadakis M; Hadley G; Cai R; Buchan AM JAMA Neurol; 2014 May; 71(5):634-9. PubMed ID: 24590416 [TBL] [Abstract][Full Text] [Related]
13. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Green AR Clin Exp Pharmacol Physiol; 2002 Nov; 29(11):1030-4. PubMed ID: 12366397 [TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
15. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. Feuerstein GZ; Zaleska MM; Krams M; Wang X; Day M; Rutkowski JL; Finklestein SP; Pangalos MN; Poole M; Stiles GL; Ruffolo RR; Walsh FL J Cereb Blood Flow Metab; 2008 Jan; 28(1):217-9. PubMed ID: 17579658 [TBL] [Abstract][Full Text] [Related]
16. The High Cost of Stroke and Stroke Cytoprotection Research. Lapchak PA; Zhang JH Transl Stroke Res; 2017 Aug; 8(4):307-317. PubMed ID: 28039575 [TBL] [Abstract][Full Text] [Related]
17. Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Lapchak PA Transl Stroke Res; 2013 Dec; 4(6):704-9. PubMed ID: 24323424 [No Abstract] [Full Text] [Related]
18. Drug therapy in stroke: from preclinical to clinical studies. Kaur H; Prakash A; Medhi B Pharmacology; 2013; 92(5-6):324-34. PubMed ID: 24356194 [TBL] [Abstract][Full Text] [Related]
19. Novel multi-functional nitrones for treatment of ischemic stroke. Sun Y; Zhang G; Zhang Z; Yu P; Zhong H; Du J; Wang Y Bioorg Med Chem; 2012 Jun; 20(12):3939-45. PubMed ID: 22579617 [TBL] [Abstract][Full Text] [Related]